Ago2 Antibody, Brachyury Antibody, Brn3A Antibody, Cd45Ro Antibody, Cdk5 Antibody, Erg Antibody, Foxa2 Antibody, Galr1 Antibody, Gerbil, Guinea, Hamster, Helicobacter, Human, Influenza, Insect, Kangaroo, Killifish, Klf2 Antibody, Lkb1 Antibody, Mobp Antibody, Parp1 Antibody, Pig, Raccoon, Rat, Reindeer, Reptile, Tbp Antibody, Zeb2 Antibody

Rapid purification and direct microassay of calbindin9kDa utilizing its solubility in perchloric acid.

The 9 kDa calcium-binding protein, calbindin9kDa, was discovered to be soluble in 7% (v/v) perchloric acid. Calbindin9kDa was simply purified from rat duodenum in 1 day with perchloric acid precipitation adopted by reverse-phase h.p.l.c. The yield was 21.4 +/- 2.Three nmol/g moist weight of tissue (imply +/- S.E.M.; n = 3) from usually fed 7-8-week-old rats (approx. 70% restoration).
The purification was additionally efficient with rabbit duodenum calbindin9kDa, however not with numerous different EF-hand calcium-binding proteins examined within the rat. A number of standards (h.p.l.c., u.v. spectrum, denaturing two-dimensional PAGE, N-terminal sequencing) indicated that the rat calbindin9kDa was purified to homogeneity and was not affected by proteolysis.
Excessive-affinity calcium-binding properties have been retained and no proof of isoforms or cost modification was noticed. Residue 59, recognized as Asn (not Asp as beforehand reported), was totally amidated. When adopted as a microassay with isocratic h.p.l.c., the perchloric acid process enabled speedy (lower than 6 min) and direct (peptide bond absorbance) quantification of lower than 1 pmol of calbindin9kDa. This new strategy to purification and assay can be of specific utility for investigations of calbindin9kDa in beforehand intractable low-abundance sources (e.g. cultured cells).

Detection of GPCR mRNA Expression in Major Cells Through qPCR, Microarrays, and RNA-Sequencing

 

A workflow is described for assaying the expression of G protein-coupled receptors (GPCRs) in cultured cells, utilizing a mix of strategies that assess GPCR mRNAs. Starting from the isolation of cDNA and preparation of mRNA, we offer protocols for designing and testing qPCR primers, assaying mRNA expression utilizing qPCR and high-throughput evaluation of GPCR mRNA expression by way of TaqMan qPCR-based, GPCR-selective arrays.

We additionally present a workflow for evaluation of expression from RNA-sequencing (RNA-seq) assays, which could be queried to yield expression of GPCRs and associated genes in samples of curiosity, in addition to to check adjustments in expression between teams, reminiscent of in cells handled with medication or from wholesome and diseased topics.

We place precedence on optimized protocols that distinguish sign from noise, as GPCR mRNAs are sometimes current in low abundance, necessitating methods that maximize sensitivity whereas minimizing noise. These strategies might also be relevant for assessing the expression of members of households of different low abundance genes by way of high-throughput analyses of mRNAs, adopted by unbiased affirmation and validation of outcomes by way of qPCR.

Responsive Hydrogel Binding Matrix for Twin Sign Amplification in Fluorescence Affinity Biosensors and Peptide Microarrays

 

A mixed strategy to sign enhancement in fluorescence affinity biosensors and assays is reported. It’s based mostly on the compaction of particularly captured goal molecules on the sensor floor adopted by optical probing with a tightly confined floor plasmon (SP) subject. This idea is utilized through the use of a thermoresponsive hydrogel (HG) binding matrix that’s ready from a terpolymer derived from poly(N-isopropylacrylamide) (pNIPAAm) and hooked up to a metallic sensor floor. Epi-illumination fluorescence and SP-enhanced whole inner reflection fluorescence readouts of affinity binding occasions are carried out to spatially interrogate the fluorescent sign within the course parallel and perpendicular to the sensor floor.

The pNIPAAm-based HG binding matrix is organized in arrays of sensing spots and employed for the particular detection of human IgG antibodies in opposition to the Epstein-Barr virus (EBV). The detection is carried out in diluted human plasma or with remoted human IgG through the use of a set of peptide ligands mapping the epitope of the EBV nuclear antigen. Alkyne-terminated peptides have been covalently coupled to the pNIPAAm-based HG carrying azide moieties. Importantly, utilizing such low-molecular-weight ligands allowed preserving the thermoresponsive properties of the pNIPAAm-based structure, which was not doable for amine coupling of normal antibodies which have the next molecular weight.

Microarray evaluation reveals an inflammatory transcriptomic signature in peripheral blood for sciatica

 

Background: Though the pathology of sciatica has been studied extensively, the transcriptional adjustments within the peripheral blood brought on by sciatica haven’t been characterised. This examine aimed to characterize the peripheral blood transcriptomic signature for sciatica.

Strategies: We used a microarray to determine differentially expressed genes within the peripheral blood of sufferers with sciatica in contrast with that of wholesome controls, carried out a useful evaluation to disclose the peripheral blood transcriptomic signature for sciatica, and performed a community evaluation to determine key genes that contribute to the noticed transcriptional adjustments. The expression ranges of those key genes have been assessed by qRT-PCR.

Outcomes: We discovered that 153 genes have been differentially expressed within the peripheral blood of sufferers with sciatica in contrast with that of wholesome controls, and 131 and 22 of those have been upregulated and downregulated, respectively. A useful evaluation revealed that these differentially expressed genes (DEGs) have been strongly enriched for the inflammatory response or immunity. The community evaluation revealed {that a} group of genes, most of that are associated to the inflammatory response, performed a key function within the dysregulation of those DEGs. These key genes are Toll-like receptor 4, matrix metallopeptidase 9, myeloperoxidase, cathelicidin antimicrobial peptide, resistin and Toll-like receptor 5, and a qRT-PCR evaluation validated the upper transcript ranges of those key genes within the peripheral blood of sufferers with sciatica than in that of wholesome controls.

Conclusion: We revealed inflammatory traits that function a peripheral blood transcriptomic signature for sciatica and recognized genes which can be important for mRNA dysregulation within the peripheral blood of sufferers with sciatica.

Metabolic utilization of human osteoblast cell line hFOB 1.19 beneath normoxic and hypoxic situations: A phenotypic microarray evaluation

At the moment, researchers perceive that bone cells expertise hypoxia throughout bone harm or fracture. Such stress situation exerts impact on bone regeneration and restore. Nonetheless, there’s restricted data on the metabolites and metabolism adjustments that happen in osteoblast cells after they bear inherent regeneration and restore beneath hypoxia. This manuscript describes the usage of Phenotype MicroArrays to watch the response of human osteoblast cells beneath normoxic and hypoxic situations when it comes to cell development and utilization of metabolites.

The human osteoblast cultured beneath these two completely different oxygen concentrations confirmed completely different development curve and utilization of metabolites, suggesting oxygen ranges play a task in bone restore and therapeutic. We’ve got deduced the principle metabolites for osteoblast cells to provide vitality beneath normoxic and hypoxic situations. The brand new findings on this analysis assist researchers to grasp how hypoxia can affect utilization of metabolites in osteoblast cells, which function vital data to enhance strategies for bone regeneration.

expressionpathology
expressionpathology

GEOlimma: differential expression evaluation and have choice utilizing pre-existing microarray information

Background: Differential expression and have choice analyses are important steps for the event of correct diagnostic/prognostic classifiers of difficult human ailments utilizing transcriptomics information. These steps are significantly difficult as a result of curse of dimensionality and the presence of technical and organic noise. A promising technique for overcoming these challenges is the incorporation of pre-existing transcriptomics information within the identification of differentially expressed (DE) genes. This strategy has the potential to enhance the standard of chosen genes, improve classification efficiency, and improve organic interpretability. Whereas a lot of strategies have been developed that use pre-existing information for differential expression evaluation, present strategies don’t leverage the identities of experimental situations to create a strong metric for figuring out DE genes.

Outcomes: On this examine, we suggest a novel differential expression and have choice method-GEOlimma-which combines pre-existing microarray information from the Gene Expression Omnibus (GEO) with the widely-applied Limma methodology for differential expression evaluation.

We first quantify differential gene expression throughout 2481 pairwise comparisons from 602 curated GEO Datasets, and we convert differential expression frequencies to DE prior chances. Genes with excessive DE prior chances present enrichment in cell development and dying, sign transduction, and cancer-related organic pathways, whereas genes with low prior chances have been enriched in sensory system pathways.

We then utilized GEOlimma to 4 differential expression comparisons inside two human illness datasets and carried out differential expression, function choice, and supervised classification analyses. Our outcomes counsel that use of GEOlimma offers higher experimental energy to detect DE genes in comparison with Limma, resulting from its elevated efficient pattern dimension. Moreover, in a supervised classification evaluation utilizing GEOlimma as a function choice methodology, we noticed related or higher classification efficiency than Limma given small, noisy subsets of an bronchial asthma dataset.

Conclusions: Our outcomes exhibit that GEOlimma is a simpler methodology for differential gene expression and have choice analyses in comparison with the usual Limma methodology. Because of its concentrate on gene-level differential expression, GEOlimma additionally has the potential to be utilized to different high-throughput organic datasets.

Mouse Anti-Human LEC

MBS690207-05mg 0.5mg
EUR 525

Mouse Anti-Human LEC

MBS690207-5x05mg 5x0.5mg
EUR 2080

Anti-Human LEC (CCL16)

MBS550695-01mg 0.1mg
EUR 260

Anti-Human LEC (CCL16)

MBS550695-02mg 0.2mg
EUR 335

Recombinant Human LEC

MBS7608806-005mg 0.05mg
EUR 345

Recombinant Human LEC

MBS7608806-02mg 0.2mg
EUR 635

Recombinant Human LEC

MBS7608806-1mg 1mg
EUR 1800

Recombinant Human LEC

MBS7608806-5x1mg 5x1mg
EUR 6955

Recombinant Human LEC (CCL16)

Z100325 25 µg
EUR 235
Description: CCL16 is a CC chemokine that specifically attracts lymphocytes, dendritic cells, and monocytes; increases their adhesive properties and has myelosuppressive activity. It is constitutively expressed in liver and is increased by interleukin 10 (IL-10) in activated monocytes. CCL16 is present in human plasma suggesting that it may be active outside hepatic tissue. CCR1, CCR2, CCR5, and CCR8 are the functional receptors of this chemokine.

Recombinant Human LEC (CCL16)

Z100329 1.0 mg
EUR 3900
Description: CCL16 is a CC chemokine that specifically attracts lymphocytes, dendritic cells, and monocytes; increases their adhesive properties and has myelosuppressive activity. It is constitutively expressed in liver and is increased by interleukin 10 (IL-10) in activated monocytes. CCL16 is present in human plasma suggesting that it may be active outside hepatic tissue. CCR1, CCR2, CCR5, and CCR8 are the functional receptors of this chemokine.

Recombinant Human LEC (CCL16)

MBS4159662-0025mg 0.025mg
EUR 385

Recombinant Human LEC (CCL16)

MBS4159662-1mg 1(mg)
EUR 4600

Recombinant Human LEC (CCL16)

MBS4159662-5x1mg 5x1mg
EUR 20445

Human LEC (CCL16) Recombinant

MBS553045-0005mg 0.005mg
EUR 165

Human LEC (CCL16) Recombinant

MBS553045-0025mg 0.025mg
EUR 245

Anti-Human LEC/NCC-4 Antibody

102-P51G 100 µg
EUR 245.7
Description: LEC or NCC-4 is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.

Human LEC/CCL16 Antibody Pair Set

ABPR-ZB293 5 plates, 15 plates Ask for price
Description: Quantitative determination of Human LEC/CCL16

Anti-Human LEC Goat Polyclonal Antibody

TA328365 100 µg Ask for price

Human LEC/NCC-4 (CCL16)

MBS692056-0005mg 0.005mg
EUR 300

Human LEC/NCC-4 (CCL16)

MBS692056-002mg 0.02mg
EUR 450

Human LEC/NCC-4 (CCL16)

MBS692056-5x002mg 5x0.02mg
EUR 1725

Recombinant Human LEC (CCL16) Protein

PROTO15467-1 20ug
EUR 380.4
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.

Recombinant Human LEC/CCL16 protein

CD01396-5ug 5ug
EUR 176
Description: Human CCL16, also called Liver-expressed chemokine (LEC), Monotactin-1 (MTN-1), IL-10-inducible chemokine and so on, is expressed by the CCL16 gene located on the chromosome 17 in humans. The gene encodes a 120 a.a. residue precursor protein with a 23 a.a. residue predicted signal peptide that is cleaved to generate a 97 a.a. residue mature protein. The protein is secreted by the liver, thymus, spleen cells and showing chemotactic activity for lymphocytes and monocytes but it is distantly related to other CC chemokines, exhibiting less than 30 % sequence identity. CCL16 is highly induced by IL-10, IFN-γ and bacterial lipopolysaccharide in monmcytes and signal through CCR1, CCR2, CCR5, and CCR8.

LEC/NCC-4 Human Recombinant

rAP-0241 Inquiry Ask for price

Human LEC Recombinant Protein Lyophilized

IHULECRLY5UG each
EUR 341
Description: Human LEC Recombinant Protein Lyophilized

Human LEC Recombinant Protein Lyophilized

MBS8432637-INQUIRE INQUIRE Ask for price

LEC antibody

10R-L115A 500 ug
EUR 240
Description: Mouse monoclonal LEC antibody

LEC antibody

70R-LG003 50 ug
EUR 312
Description: Affinity purified Goat polyclonal LEC antibody

LEC antibody

MBS532318-05mg 0.5mg
EUR 370

LEC antibody

MBS532318-5x05mg 5x0.5mg
EUR 1525

LEC antibody

MBS535708-005mg 0.05mg
EUR 465

LEC antibody

MBS535708-5x005mg 5x0.05mg
EUR 1945

Biotinylated Anti-Human LEC Goat Polyclonal Antibody

TA328364 50 µg Ask for price

Recombinant Human LEC/NCC-4 (CCL16)

7-01792 5µg Ask for price

Recombinant Human LEC/NCC-4 (CCL16)

7-01793 20µg Ask for price

Recombinant Human LEC/NCC-4 (CCL16)

7-01794 1mg Ask for price

Recombinant Human LEC/NCC-4 (CCL16)

HECCP-1601 5ug Ask for price

Recombinant Human LEC/NCC-4 (CCL16)

MBS143272-0005mg 0.005mg
EUR 240

Recombinant Human LEC/NCC-4 (CCL16)

MBS143272-002mg 0.02mg
EUR 310

Recombinant Human LEC/NCC-4 (CCL16)

MBS143272-1mg 1mg
EUR 2880

Recombinant Human LEC/NCC-4 (CCL16)

MBS143272-5x1mg 5x1mg
EUR 12630

LEC/CCL16 Matched ELISA Antibody Pair Set, Human

MBS8118261-15Plates 15Plates
EUR 600

LEC/CCL16 Matched ELISA Antibody Pair Set, Human

MBS8118261-5Plates 5Plates
EUR 345

LEC/CCL16 Matched ELISA Antibody Pair Set, Human

MBS8118261-5x15Plates 5x15Plates
EUR 2755

HCC-4, LEC, NCC-4, CCL16, human

RC315-27 5ug
EUR 125.26

Human LEC/NCC-4 (CCL16) Recombinant Protein

100-060 20 µg
EUR 196.35
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.

Human LEC/NCC-4 (CCL16) Recombinant Protein

100-060S 5 µg
EUR 92.4
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.

LEC (CCL16) (NM_004590) Human Over-expression Lysate

LS006360 100ug
EUR 628
Description: Transient overexpression lysate of chemokine (C-C motif) ligand 16 (CCL16)

CCL16 LEC/NCC-4 Human Recombinant Protein

PROTO15467 Regular: 20ug
EUR 380.4
Description: CCL16 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 97 amino acids and having a molecular mass of 11.2 kDa. ;The CCL16 is purified by proprietary chromatographic techniques.

LEC/CCL16 Protein, Human, Recombinant (His Tag)

MBS8120314-005mg 0.05mg
EUR 340

LEC/CCL16 Protein, Human, Recombinant (His Tag)

MBS8120314-1mg 1mg
EUR 2530

LEC/CCL16 Protein, Human, Recombinant (His Tag)

MBS8120314-5x1mg 5x1mg
EUR 11240

LEC/CCL16 Protein, Human, Recombinant (His Tag)

MBS8120315-005mg 0.05mg
EUR 340

LEC/CCL16 Protein, Human, Recombinant (His Tag)

MBS8120315-5x005mg 5x0.05mg
EUR 1380

LEC, NCC-4, Human (Liver-Expressed Chemokine)

MBS635010-0005mg 0.005mg
EUR 340

LEC, NCC-4, Human (Liver-Expressed Chemokine)

MBS635010-002mg 0.02mg
EUR 490

LEC, NCC-4, Human (Liver-Expressed Chemokine)

MBS635010-5x002mg 5x0.02mg
EUR 2055

LEC Chemokine(LEC66) Antibody

BNC040066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF405S conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC040066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF405S conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC040067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF405S conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC040067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF405S conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC810066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF680R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC810066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF680R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC810067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF680R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC810067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF680R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC940066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF594 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC940066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF594 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC940067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF594 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC940067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF594 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC880066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF488A conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC880066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF488A conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC880067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF488A conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC880067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF488A conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC430066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF543 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC430066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF543 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC430067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF543 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC430067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF543 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC050066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF405M conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC050066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF405M conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC050067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF405M conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC050067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF405M conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC470066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF647 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC470066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF647 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC470067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF647 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC470067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF647 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC400066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF640R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody

BNC400066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF640R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC400067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF640R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody

BNC400067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF640R conjugate, Concentration: 0.1mg/mL

 

Frank Green